Renal Function Tests (RFT) and Biomarkers

Overview

1. Traditional / Conventional RFT

A. Serum Creatinine

• Males: ~0.7-1.2 mg/dL
• Females: ~0.5-1.0 mg/dL

1. Muscle mass effect - Production varies greatly with age, sex, and muscle mass (24-hr creatinine excretion falls from 23.8 mg/kg in men aged 20-29 to 9.8 mg/kg in men aged 90-99)
2. Non-specificity for tubular injury - Does not distinguish prerenal, intrinsic, or postrenal causes; cannot localize glomerular vs. tubular vs. proximal vs. distal injury
3. Lag time - Static measurements do not reflect real-time GFR changes; creatinine accumulates over hours to days
4. Drug interference - Cimetidine and trimethoprim inhibit tubular secretion, raising creatinine without affecting true GFR
5. Assay interference - The Jaffé (alkaline picrate) method overestimates creatinine by ~25% due to noncreatinine chromogens (proteins, glucose, acetoacetate)
6. CKD misclassification - Small changes in serum creatinine in patients with pre-existing CKD may falsely classify them as having AKI

• Jaffé (alkaline picrate) reaction - standard but subject to chromogen interference
• Enzymatic assays (creatininase method) - more specific, preferred in diabetic patients

B. Blood Urea Nitrogen (BUN)

• Highly non-specific - BUN rises with high protein intake, catabolic states (fever, burns, trauma, corticosteroids, sepsis), GI bleeding, and decreased tubular flow (dehydration, obstruction)
• Tubular reabsorption - Urea is passively reabsorbed in tubules; anything that slows tubular flow (volume depletion) raises BUN disproportionately
• BUN:Creatinine ratio - >20:1 suggests prerenal azotemia; <10:1 may suggest liver disease or malnutrition
• Advanced CKD - Averaging urea clearance and creatinine clearance can be more accurate at low GFR, since creatinine clearance overestimates and urea clearance underestimates true GFR

C. Creatinine Clearance and eGFR

• Formula: CrCl = (Urine Creatinine × Urine Volume) / Serum Creatinine
• Requires 24-hour urine collection; prone to collection errors (skipped voids = underestimation)
• Overestimates true GFR because of tubular secretion of creatinine

• Cockcroft-Gault: uses age, sex, weight, and serum creatinine
• MDRD (4-variable): uses age, sex, race, and serum creatinine
• CKD-EPI: more accurate across the range of GFR; preferred current standard
• CKD-EPI Cystatin C equation: combines creatinine + cystatin C for improved accuracy

D. Urinalysis

• Protein - Semiquantitative; positive result prompts 24-hr protein quantification (proteinuria >3.5 g/day = nephrotic range). Types: glomerular, tubular, overflow, tissue
• Blood/hematuria - >2 RBCs/HPF is abnormal; may indicate glomerulonephritis, stones, or infection
• Glucose - Indicates either hyperglycemia or proximal tubular dysfunction (Fanconi syndrome)
• Nitrites/leukocyte esterase - Screens for UTI
• pH, specific gravity - Reflects concentrating ability (normal SG 1.001-1.035; >1.018 indicates preserved concentrating function)

• Granular/muddy brown casts - Diagnostic of acute tubular necrosis (ATN)
• Red cell casts - Pathognomonic of glomerulonephritis
• White cell casts - Acute pyelonephritis or interstitial nephritis
• Fatty casts (oval fat bodies) - Nephrotic syndrome

• Urine sodium <20 mEq/L - Prerenal (kidney retaining sodium)
• Urine sodium >40 mEq/L - Intrinsic renal injury (tubular inability to retain sodium)
• Fractional Excretion of Sodium (FENa) <1% - Prerenal; >2% - ATN

2. Novel Filtration Markers

Cystatin C

• Freely filtered at the glomerulus
• Neither secreted nor reabsorbed, but fully catabolized by proximal tubular cells (making urinary cystatin C a tubular injury marker)
• Less influenced by muscle mass than creatinine
• Short half-life (~2 hours) - responds more rapidly to acute changes in GFR

• Better predictor of risk for death and ESRD across diverse populations
• Elevated in >50% of persons aged >80 (reflecting true GFR decline in elderly)
• CKD-EPI Cystatin C equation improves CKD classification and risk stratification vs. creatinine-based equations alone
• Serum cystatin C also associated with cardiovascular risk

Proenkephalin A 119-159 (penKid)

3. Novel Tubular Injury Biomarkers (AKI Biomarkers)

RIFLE and KDIGO AKI Staging (for context)

A. Kidney Injury Molecule-1 (KIM-1)

• Type I cell membrane glycoprotein with an immunoglobulin-like domain and mucin domain
• KIM-1 mRNA increases more than any other known gene after kidney injury
• Its ectodomain is shed into urine after proximal tubular injury
• Earlier diagnostic indicator of AKI than plasma creatinine or BUN in preclinical and clinical studies
• High specificity - no systemic source detected; expression limited to the kidney
• Induced by many nephrotoxins: cisplatin, cyclosporin, cadmium, gentamicin, mercury, chromium
• NGAL is more sensitive at earliest time points; KIM-1 adds specificity at later time points

B. Neutrophil Gelatinase-Associated Lipocalin (NGAL)

• 25-kDa protein initially identified bound to gelatinase in neutrophil granules
• Also known as lipocalin-2 (LCN2) or human neutrophil lipocalin (HNL)
• Synthesized during granulocyte maturation; induced in epithelial cells during inflammation
• Detectable in urine as early as 3 hours after cisplatin administration in animal models
• Most sensitive marker at earliest time points after AKI
• Validated in pediatric and adult patients undergoing cardiopulmonary bypass (CPB) for cardiac surgery
• Available as both serum and urine measurements
• Limitations: also elevated in inflammatory conditions (sepsis, malignancy), reducing specificity

C. Interleukin-18 (IL-18)

• 18-kDa proinflammatory cytokine activated by caspase-1
• Produced by renal tubule cells and macrophages; mediates neutrophil and monocyte infiltration in tubular injury
• In humans, IL-18 is induced and cleaved mainly in proximal tubules and released into urine
• Participates in: ischemia-reperfusion injury, allograft rejection, infection, autoimmune disease, and malignancy
• Measured by commercially available ELISA and microbead assays
• TRIBE-AKI Study (1,219 adults undergoing cardiac surgery): IL-18 significantly predicted AKI before creatinine rise
• Higher IL-18 in acute tubular necrosis vs. prerenal azotemia or UTI (original validation study by Parikh et al., 72 patients)

D. Fatty Acid-Binding Protein (FABP)

• Liver-type (L-FABP) and heart-type (H-FABP) variants both studied as AKI biomarkers
• H-FABP is a promising biomarker particularly in cardiac surgery and ICU-associated AKI

E. α1-Microglobulin

• Low-molecular-weight glycoprotein (~27-30 kDa); member of the lipocalin superfamily
• Primarily synthesized by liver; freely filtered at glomerulus and completely reabsorbed/catabolized by normal proximal tubule (via megalin-mediated uptake)
• Urinary α1-microglobulin elevation = proximal tubular injury or dysfunction
• Reference ranges: <13 mg/g creatinine (age <50); <20 mg/g creatinine (age ≥50)
• More stable than β2-microglobulin across a range of urine pH, making it a more reliable biomarker
• Associated with increased risk of CKD and all-cause mortality

F. N-acetyl-β-D-glucosaminidase (NAG)

• Lysosomal enzyme from proximal tubular cells; too large to be filtered, so any urinary NAG = tubular cell damage
• Sensitive marker of tubular injury in diabetic nephropathy and nephrotoxin exposure

G. TIMP-2 × IGFBP-7 (Cell Cycle Arrest Markers)

• Urinary TIMP-2 (tissue inhibitor of metalloproteinase-2) × IGFBP-7 (insulin-like growth factor binding protein-7) product
• Both are G1 cell cycle arrest markers expressed in stressed tubular cells before injury manifests
• FDA-cleared NephroCheck® test
• Clinical utility: Urinary TIMP-2 × IGFBP-7 is associated with increased risk of KDIGO stage 2 or 3 AKI within the next 12 hours in ICU patients at high risk for AKI
• AUC ~0.80 in validation studies

H. Hepcidin-25

• An iron-regulatory peptide showing promise in cardiac surgery AKI
• Lower urinary hepcidin-25 on postoperative day 1 is associated with AKI development
• AUC ~0.80 in preliminary studies
• Combining hepcidin-25 with postoperative NGAL improves AUC to ~0.84

I. Other Novel Biomarkers (Emerging)

4. CKD-Specific Biomarkers

• Plasma TGFR1, TGFR2 - TGF-β pathway markers increasingly recognized as markers of CKD progression
• Plasma EGF - Epidermal growth factor; associated with CKD progression
• Urinary α1-microglobulin - Associated with CKD development and all-cause mortality
• Serum cystatin C - Predicts cardiovascular morbidity and mortality even beyond its GFR-estimating role
• Albuminuria - 30-300 mg/day = microalbuminuria (early diabetic nephropathy); >300 mg/day = macroalbuminuria

5. Summary Comparison Table

Clinical Takeaways

1. Serum creatinine and BUN detect injury only after at least 50% nephron loss - they are "lagging indicators."
2. Novel biomarkers (NGAL, KIM-1, IL-18, TIMP-2 × IGFBP-7) detect subclinical tubular injury in the window before creatinine rises.
3. Cystatin C is the best validated replacement for creatinine as a GFR marker, especially in the elderly, low muscle mass, or obesity.
4. NGAL is the most sensitive early marker; KIM-1 adds kidney-specificity at later time points.
5. TIMP-2 × IGFBP-7 is the only FDA-cleared test for AKI risk stratification in ICU patients.
6. Urinalysis + microscopy remains an essential and cost-free component of every renal evaluation - muddy brown casts are pathognomonic of ATN.

• Henry's Clinical Diagnosis and Management by Laboratory Methods (AKI biomarkers, RIFLE/KDIGO staging)
• Brenner and Rector's The Kidney, 2-Volume Set (cystatin C, α1-microglobulin, creatinine limitations, CKD biomarkers)
• Barash, Cullen, and Stoelting's Clinical Anesthesia (urinalysis, GFR-creatinine relationship, BUN)
• Miller's Anesthesia, 10e (novel biomarkers, cystatin C, penKid)
• Current Surgical Therapy, 14e (AKI biomarker candidate overview)